Selinexor and the Selective Inhibition of Nuclear Export: A New Perspective on the Treatment of Sarcomas and Other Solid and Non-Solid Tumors
Antonella Lucia Marretta,
Giuseppe Di Lorenzo,
Dario Ribera,
Lucia Cannella,
Claudia von Arx,
Alessandra Bracigliano,
Ottavia Clemente,
Roberto Tafuto,
Antonio Pizzolorusso,
Salvatore Tafuto
Affiliations
Antonella Lucia Marretta
Department of Clinical and Surgery Oncology Unit, University of Naples “Federico II”, Via S. Pansini 5, 80131 Naples, Italy
Giuseppe Di Lorenzo
Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori—IRCCS, Fondazione “G. Pascale”, 80131 Naples, Italy
Dario Ribera
Department of Clinical and Surgery Oncology Unit, University of Naples “Federico II”, Via S. Pansini 5, 80131 Naples, Italy
Lucia Cannella
Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori—IRCCS, Fondazione “G. Pascale”, 80131 Naples, Italy
Claudia von Arx
Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori—IRCCS, Fondazione “G. Pascale”, 80131 Naples, Italy
Alessandra Bracigliano
Nuclear Medicine Unit, Istituto Nazionale Tumori—IRCCS, Fondazione “G. Pascale”, Via M. Semmola 53, 80131 Naples, Italy
Ottavia Clemente
Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori—IRCCS, Fondazione “G. Pascale”, 80131 Naples, Italy
Roberto Tafuto
Division of Neurosurgery, University of Naples “Federico II”, Via S. Pansini 5, 80131 Naples, Italy
Antonio Pizzolorusso
Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori—IRCCS, Fondazione “G. Pascale”, 80131 Naples, Italy
Salvatore Tafuto
Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori—IRCCS, Fondazione “G. Pascale”, 80131 Naples, Italy
Nucleocytoplasmic transport has been found dysregulated in many types of cancer and is often described as a poor prognostic factor. Specifically, Exportin-1 (XPO1) has been found overexpressed in many tumors and has become an attractive target in molecular oncology and therapeutics development. The selective inhibitor of nuclear export, Selinexor, is one of the most scientifically interesting drugs that targets XPO1 in clinical development. In this review, we summarized the most relevant preclinical and clinical results achieved for non-solid tumors, sarcomas, and other kind of solid tumors.
